Bio Medica Laboratories Limited
BMLLNSE
₹155.00▼ -0.50 (-0.32%)
Whole company worth₹196 Cr
Price for ₹1 of profit₹12
1-year range₹102 – ₹181
The short version
A fast-growing, highly profitable business — priced low for what it earns.
What Bio Medica Laboratories does
Incorporated in August 2015, Bio Medica Laboratories Ltd specialises in manufacturing pharmaceutical parenteral formulations, producing a wide range of ethical drugs, generic drugs, and over-the -counter (OTC) medications
Worked out from Bio Medica Laboratories's own filed results and exchange data, in plain words. Where a finance term matters, we say what it means.
01What does it do?
Bio Medica Laboratories is a micro-sized company in pharmaceuticals.
Incorporated in August 2015, Bio Medica Laboratories Ltd specialises in manufacturing pharmaceutical parenteral formulations, producing a wide range of ethical drugs, generic drugs, and over-the -counter (OTC) medications
- Whole company is worth
- ₹196 crore
- Shareholders
- 331 people
- Listed since
- 2026
A very small company by stock-market value — prices can swing hard and trading can be thin.
02Is it growing?
Sales have grown 38% a year for 3 years.
At that pace a business doubles in size roughly every 2 years. Profit grew even faster, at 229% a year — the business is keeping more of each rupee it brings in.
Point at a bar for exact figures · amounts in ₹ crore
03Does it make money?
Out of every ₹100 it sells, it keeps ₹27 as profit.
Here is where the money from Bio Medica Laboratories's sales went in FY26, the latest full year it has reported.
₹41
₹14
₹10
₹27
- ₹41Making or buying what it sellsraw materials, stock, goods bought for resale
- ₹14Running the businessstaff, rent, marketing, power and everything else
- ₹5.2Interest on its loansthe cost of borrowed money
- ₹2.7Wear and tearmachines, stores and buildings losing value over time
- ₹10Taxincome tax paid to the government
- ₹27Profit it keepswhat is left for the company's owners
On the money its owners have put in
It earns ₹44 a year on every ₹100 its owners have invested.
Bank FD ~₹6–7
₹44
₹0₹10₹20₹30₹40₹50
That figure is called return on equity (ROE). Above ₹20 is rare and usually means the business has something competitors struggle to copy. For comparison, a bank fixed deposit pays roughly ₹6–7.
Does the profit turn into cash?
For every ₹100 of profit it reported, ₹-34 actually came in as cash.
Profit it reported₹24 Cr
Cash its business brought in−₹8.1 Cr
Over the last 3 years: ₹24 crore of profit but only −₹8.1 crore of cash. A wide gap like this is worth understanding before trusting the profit figure.
04Is the price high or low?
You pay ₹12 for every ₹1 of profit it makes in a year.
This is the P/E ratio: share price divided by a year's profit per share. A P/E of 12 means buyers are paying for about 12 years of today's profit up front.
The share price over the past year
It is 14% below its highest price of the past year and 53% above its lowest.
05Who owns it?
Its founders and parent group own 68 of every 100 shares — they control the company.
If the company were split into 100 equal shares, this is who would hold them. 331 people and institutions hold its shares.
As filed for the quarter ending 30 Sept 2026. Arrows show the change since the quarter before, in percentage points.
06What is going well, and what to watch
Two things going well, two things worth watching.
Picked out of the numbers above by fixed rules — the same rules for every company — so nothing here is somebody's opinion.
Going well
- Sales have compounded at 38% a year.
- Earns ₹44 a year on every ₹100 of shareholders' money.
Worth watching
- Owes ₹1.5 of debt for every ₹1 its owners have in the business.
- Thinly traded — only about ₹29 lakh of shares change hands a day, so buying or selling can move the price.
07What happened lately?
Its latest quarter.
Jan–Mar 2026 is the most recent quarter it has reported. Each figure is compared with the same three months a year earlier, because many businesses sell more in some seasons than others.
Sales
₹43 Cr
Profit
₹12 Cr
No notable developments in the last few weeks.
Advanced view
Every number, every table, the full chart.
Ten years of statements, quarterly results, peers side by side, technical indicators, analyst estimates, bulk deals and filings.
Ask DoXy
Still have a question about Bio Medica Laboratories?
This page describes Bio Medica Laboratories using its reported figures and exchange data. It is for information only and is not investment advice or a recommendation to buy, sell or hold. DocStoX is not a SEBI-registered investment adviser or research analyst.
Bio Medica Laboratories Limited (BMLL): company summary
The company's business is improving, with annual revenue rising 12.8% and annual net profit increasing 20.3%.
Bio Medica Laboratories Limited (BMLL) is a micro-cap Healthcare company valued at ₹196 crore operating in Pharmaceuticals on the NSE and BSE.
- Recent price move
- Bio Medica Laboratories Limited last traded at ₹155, modestly down 0.32% on the day.
- Financial performance
- The company's business is improving, with annual revenue rising 12.8% and annual net profit increasing 20.3%. The latest quarter shows revenue of ₹43 crore and net profit of ₹12 crore, both matching the annual figures. The net profit margin widened to 27.3% from 25.6% in the prior year, while return on equity remained at 44.4%.
- Valuation multiples
- The stock trades at 12.0 times earnings, a discount to the Healthcare median of 32.0, 2.73 times book value.
- Things to watch
- The company has a high debt to equity ratio of 1.51. It is not paying out dividend despite repeated profits. The stock is 9.1% below its 52-week high.
- Where it stands
- The company is reporting strong growth in revenue and net profit, with a widening net profit margin. The stock is 9.1% below its 52-week high.
Summarised by DocStoX's model on 2026-10-18 from company filings, exchange data and news. This is a factual summary, not a rating or a recommendation. Informational only, not investment advice. Consult a SEBI-registered adviser before investing.
More Healthcare stocks · Pharmaceuticals
Explore Bio Medica Laboratories Limited’s valuation
Free deep-dive tools · no sign-up
Fair ValueOur fair-value estimate, upside, and Bear/Base/Bull scenarios.Intrinsic ValueGraham & earnings-power intrinsic value with margin of safety.DCFDiscounted cash flow — free cash flow, growth, value per share.ValuationP/E, P/B, earnings yield and the full multiples picture.Financial RatiosProfitability, leverage and efficiency ratios at a glance.PeersHow it stacks up against its closest listed competitors.
Bio Medica Laboratories Limited peers in Healthcare
Other Healthcare stocks on the NSE & BSE. See the full Healthcare sector list.
SUN PHARMACEUTICAL IND LDIVI S LABORATORIES LTDTORRENT PHARMACEUTICALS LZYDUS LIFESCIENCES LTDAPOLLO HOSPITALS ENTER. LLAURUS LABS LIMITEDCIPLA LTDDR. REDDY S LABORATORIESMANKIND PHARMA LIMITEDAUROBINDO PHARMA LTDLUPIN LIMITEDMANIPAL HEALTH ENTERPRI L
Compare Bio Medica Laboratories Limited with peers
Bio Medica Laboratories Limited vs SUN PHARMACEUTICAL IND LBio Medica Laboratories Limited vs DIVI S LABORATORIES LTDBio Medica Laboratories Limited vs TORRENT PHARMACEUTICALS LBio Medica Laboratories Limited vs ZYDUS LIFESCIENCES LTDBio Medica Laboratories Limited vs APOLLO HOSPITALS ENTER. LBio Medica Laboratories Limited vs LAURUS LABS LIMITED
Related tools & concepts
Value Bio Medica Laboratories Limited with the ratios and calculators DocStoX uses in its analysis.
P/E RatioPrice to earningsReturn on Equity (ROE)ProfitabilityROCECapital efficiencyDebt to EquityLeverageP/B RatioPrice to bookNet Profit MarginBottom-line efficiencyDCF / Intrinsic ValueEstimate fair valueCAGR CalculatorAnnualised returnDividend YieldIncome on pricePosition SizeRisk-based sizingBrokerage CalculatorCharges on a tradeSIP CalculatorSystematic investing